[HTML][HTML] Underrepresentation of women in recent landmark kidney trials: the gender gap prevails
Kidney International Reports, 2022•Elsevier
Results We included 8 trials examining SGLT-2i (n= 66,309; 22,792 women [36.0%]), 3 trials
examining GLP1-RAs (n= 16,713; 5976 women [35.8%]), and 2 trials examining finerenone
(n= 13,026; 3938 women [30.2%]). A summary of trial populations is presented in
Supplementary Table S1.
examining GLP1-RAs (n= 16,713; 5976 women [35.8%]), and 2 trials examining finerenone
(n= 13,026; 3938 women [30.2%]). A summary of trial populations is presented in
Supplementary Table S1.
Results
We included 8 trials examining SGLT-2i (n= 66,309; 22,792 women [36.0%]), 3 trials examining GLP1-RAs (n= 16,713; 5976 women [35.8%]), and 2 trials examining finerenone (n= 13,026; 3938 women [30.2%]). A summary of trial populations is presented in Supplementary Table S1.
Elsevier
